二氢吡啶类钙通道拮抗剂的剂型研究进展  

Advances in Research on Dosage Form of Dihydropyridine Calcium Channel Antagonists

作　　者：覃小恒[1,2] 邹巧根[3] 张尊建[1,2] 

机构地区：[1]教育部药物质量与安全预警重点实验室,江苏南京210009 [2]中国药科大学分析测试中心,江苏南京210009 [3]南京工业大学生物与制药工程学院,江苏南京210009

出　　处：《药学进展》2011年第8期360-366,共7页Progress in Pharmaceutical Sciences

摘　　要：二氢吡啶类钙拮抗剂是目前临床应用最广泛的抗高血压药物之一,但该类药物大多存在水溶性差和半衰期短等缺点。为此,研究人员尝试通过制剂学手段对该类药物的水溶性及半衰期等参数进行改进,并获得了一定成果。介绍了国内外有关二氢吡啶类钙拮抗剂的药物剂型研究进展,旨在为该类溶解性不佳或半衰期较短的药物的制剂开发提供一定参考。Dihydropyridine calcium channel antagonists are one kind of the most widely used drugs for the treatment of hypertension, but most of them have a poor water solubility and short in vivo halflife. Recently, many scientists have been trying to improve the water solubility and half-life of these drugs by means of pharmaceutical methods, and have obtained the remarkable achievements. The recent progresses in research on the dosage forms of dihydropyridine calcium channel antagonists were introduced in this paper, so as to provide a reference for the new preparations development of the drugs having poor water solubility or short half-life.

关 键 词：二氢吡啶类钙拮抗剂 剂型 水难溶性药物 生物利用度 缓控释制剂 

分 类 号：R972.4[医药卫生—药品] R944[医药卫生—药学]